GlobalData on MSN13h
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...
snmjournals.org6h
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better
Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce ...
oncnursingnews4h
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.